Drug’s benefit to younger breast cancer patients in question

(3 stars)
The AZURE trial concluded that there was no survival benefit to adding zoledronic acid (Zometa) to standard therapy for women with early stage breast cancer. This story seemed to have trouble coming to grips with that result, unlike the HealthDay article we also reviewed.